The potential use of N-acetylcysteine in respiratory conditions
https://doi.org/10.18093/0869-0189-2024-34-1-105-113
Abstract
Currently, despite the accumulated experience with the use of N-acetylcysteine (NAC) in scientific and real clinical practice, there are a number of questions about its potential and the future prospects for its use.
The aim of this work was to summarize new data on the use of NAC in patients with various conditions, based on publications in domestic and foreign medical journals.
Results. The article presents an overview of publications in domestic and foreign medical journals devoted to the use of N-acetylcysteine (NAC) in pulmonology practice. The experience with the use of NAC in chronic bronchitis (CB), chronic obstructive pulmonary disease (COPD), bronchial asthma, community-acquired pneumonia, idiopathic pulmonary fibrosis, postinfectious bronchiectasis, and acute respiratory distress syndrome associated with COVID-19 (COronaVIrus Disease 2019) is summarized. The aspects of dose-dependent clinical effects and long-term administration of NAC in CB and COPD are analyzed. In addition, there are controversial and contradictory data on the possibility of prescribing NAC for idiopathic pulmonary fibrosis.
Conclusion. NAC is a drug with a broad spectrum of action. Due to its antioxidant and anti-inflammatory properties, minor side effects compared to other anti-inflammatory drugs even at high doses, and low price, NAC can be prescribed for many respiratory diseases. Although it has been used for more than half a century, interest in both its practical application and clinical research has not waned to this day.
Supporting agencies: The study was conducted with the support of Zambon Pharma
About the Authors
V. N. Antonov
Federal State Budgetary Educational Institution of Higher Education “South-Ural State Medical University” of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Vladimir N. Antonov, Doctor of Medicine, Professor, Department of Therapy, Institute of Additional Professional Education, Chief Researcher,
Institute of Pulmonology
ul. Vorovskogo 64, Chelyabinsk, 454092
G. L. Ignatova
Federal State Budgetary Educational Institution of Higher Education “South-Ural State Medical University” of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Galina L. Ignatova, Doctor of Medicine, Professor, Head of the Department
of Therapy, Institute of Additional Professional Education, Director of the
Institute of Pulmonology
ul. Vorovskogo 64, Chelyabinsk, 454092
M. S. Belsner
Federal State Budgetary Educational Institution of Higher Education “South-Ural State Medical University” of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Mariya S. Belsner, Candidate of Medicine, Associate Professor, Department
of Therapy, Institute of Additional Professional Education
ul. Vorovskogo 64, Chelyabinsk, 454092
References
1. Klyachkina I.L. [Do we know all about acetylcysteine?]. Farmateka. 2021; 28 (10): 103–110. DOI: 10.18565/pharmateca.2021.10.103-110 (in Russian).
2. Samuni Y., Goldstein S., Dean O.M., Berk M. The chemistry and biological activities of N-acetylcysteine. Biochim. Biophys. Acta. 2013; 1830 (8): 4117–4129. DOI: 10.1016/j.bbagen.2013.04.016.
3. Izquierdo-Alonso J.L., Pérez-Rial S., Rivera C.G., Peces-Barba G. N-acetylcysteine for prevention and treatment of COVID-19: current state of evidence and future directions. J. Infect. Public Health. 2022; 15 (12): 1477–1483. DOI: 10.1016/j.jiph.2022.11.009.
4. Avdeev S.N., Gaynitdinova V.V., Merzhoeva Z.M., Berikkhanov Z.G. N-acetylcysteine for the treatment of COVID-19 among hospitalized patients. J. Infect. 2022; 84 (1): 94–118. DOI: 10.1016/j.jinf.2021.07.003.
5. Mokra D., Mokry J., Barosova R., Hanusrichterova J. Advances in the use of N-acetylcysteine in chronic respiratory diseases. Antioxidants (Basel). 2023, 12 (9): 1713. DOI: 10.3390/antiox12091713.
6. Cazzola M., Calzetta L., Page C. et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur. Respir. Rev. 2015; 24 (137): 451–461. DOI: 10.1183/16000617.00002215.
7. Grandjean E.M., Berthet P., Ruffmann R., Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin. Ther. 2000; 22 (2): 209–221. DOI: 10.1016/S0149-2918(00)88479-9.
8. Stey C., Steurer J., Bachmann S. et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur. Respir. J. 2000; 16 (2): 253–262. DOI: 10.1034/j.1399-3003.2000.16b12.x.
9. Hansen N.C., Skriver A., Brorsen-Riis L. et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir. Med. 1994; 88 (7): 531–535. DOI: 10.1016/s0954-6111(05)80337-3.
10. Huang C., Kuo S., Lin L., Yang Y. The efficacy of N-acetylcysteine in chronic obstructive pulmonary disease patients: a meta-analysis. Ther. Adv. Respir. Dis. 2023; 17: 17534666231158563. DOI: 10.1177/17534666231158563
11. Tse H.N., Raiteri L., Wong K.Y. et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013; 144 (1): 106–118. DOI: 10.1378/chest.12-2357.
12. Liu X., Hu Z., Zhou H. N-Acetylcysteine improves inflammatory response in COPD patients by regulating Th17/Treg balance through hypoxia inducible factor-1α pathway. Biomed Res. Int. 2021; 2021: 6372128. DOI: 10.1155/2021/6372128.
13. Cazzola M., Calzetta L., Facciolo F. et al. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. Respir. Res. 2017; 18 (1): 26. DOI: 10.1186/s12931-016-0500-y.
14. Flinkman E., Vähätalo I., Tuomisto L.E. et al. Association between blood eosinophils and neutrophils with clinical features in adult-onset asthma. J. Allergy Clin. Immunol. Pract. 2023; 11 (3): 811–821.e5. DOI: 10.1016/j.jaip.2022.11.025.
15. Ministry of Health of the Russian Federation. [Guidelines: Community-acquired pneumonia in adults]. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/654_1?ysclid=lrvmev1bkv562840552 [Accessed: January 22, 2024] (in Russian).
16. Zhang Q., Ju Y., Ma Y., Wang T. N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: a randomized controlled trial. Medicine (Baltimore). 2018; 97 (45): e13087. DOI: 10.1097/MD.0000000000013087.
17. Kumar V. Pulmonary innate immune response determines the outcome of inflammation during pneumonia and sepsis-associated acute lung injury. Front. Immunol. 2020; 11: 1722. DOI: 10.3389/fimmu.2020.01722.
18. Ornatowski W., Lu Q., Yegambaram M. et al. Complex interplay between autophagy and oxidative stress in the development of pulmonary disease. Redox Biol. 2020; 36: 101679. DOI: 10.1016/j.redox.2020.101679.
19. Chen H., Ma N., Song X. et al. Protective effects of N-acetylcysteine on lipopolysaccharide-induced respiratory inflammation and oxidative stress. Antioxidants (Basel). 2022; 11 (5): 879. DOI: 10.3390/antiox11050879
20. [Adult patients with bronchiectasis: clinical guideline of European Respiratory Society]. Pul'monologiya. 2018; 28 (2): 147–168. DOI: 10.18093/0869-0189-2018-28-2-147-168 (in Russian).
21. Subhas E., Rees M. Bronchiectasis. Aust. J. Gen. Pract. 2022; 51 (12): 945–949. DOI: 10.31128/AJGP-08-22-6520.
22. Herrero-Cortina B., Alcaraz V., Vilaró J. et al. Impact of hypertonic saline solutions on sputum expectoration and their safety profile in patients with bronchiectasis: a randomized crossover trial. J. Aerosol Med. Pulm. Drug Deliv. 2018; 31 (5): 281–289. DOI: 10.1089/jamp.2017.1443.
23. Luo A., Liu X., Hu Q. et al. Efficacy of N-acetylcysteine on idiopathic or postinfective non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis protocol. BMJ Open. 2022; 12 (3): e053625. DOI: 10.1136/bmjopen-2021-053625.
24. Qi Q., Ailiyaer Y., Liu R. et al. Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial. Respir. Res. 2019; 20 (1): 73. DOI: 10.1186/s12931-019-1042-x.
25. Kondratyeva E.I., Amelina E.L., Chernukha M.Yu. et al. [Review of clinical guidelines “Cystic fibrosis”, 2020]. Pul'monologiya. 2021; 31 (2): 135–146. DOI: 10.18093/0869-0189-2021-31-2-135-146 (in Russian).
26. Ehre C., Rushton Z. L., Wang B. et al. An improved inhaled mucolytic to treat airway muco-obstructive diseases. Am. J. Respir. Crit. Care Med. 2019; 199 (2): 171–180. DOI: 10.1164/rccm.201802-0245oc.
27. Luppi F., Kalluri M., Faverio P. et al. Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management. Respir. Res. 2021; 22 (1): 109. DOI: 10.1186/s12931-021-01711-1.
28. Skov M., Pressler T., Lykkesfeldt J. et al. The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa infection – a pilot study. J. Cyst. Fibros. 2015; 14 (2): 211–218. DOI: 10.1016/j.jcf.2014.09.015.
29. Zhang R., Song Z., Guan Y. et al. Clinical efficacy and quality of life effect of acetylcysteine plus pirfenidone in patients with pulmonary fibrosis. Am. J. Transl. Res. 2022; 14 (8): 5660–5668. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452344/
30. Sakamoto S., Kataoka K., Kondoh Y. et al. Diffuse lung diseases research group of the ministry of health, labour and welfare, Japan. Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial. Eur. Respir. J. 2021; 57 (1): 2000348. DOI: 10.1183/13993003.00348-2020.
31. Avdeev S.N., Aisanov Z.R., Belevskiy A.S. et al. [Federal clinical guidelines on diagnosis and treatment of idiopathic pulmonary fibrosis]. Pul’monologiya. 2022; 32 (3): 473–495. DOI: 10.18093/0869-0189-2022-32-3-473-495 (in Russian).
32. Arber Raviv S., Alyan M., Egorov E. et al. Lung targeted liposomes for treating ARDS. J. Control. Release. 2022; 346: 421–433. DOI: 10.1016/j.jconrel.2022.03.028.
33. Cazzola M., Rogliani P., Salvi S.S. et al. Use of thiols in the treatment of COVID-19: current evidence. Lung. 2021; 199 (4): 335–343. DOI: 10.1007/s00408-021-00465-3.
34. Di Marco F., Foti G., Corsico A.G. Where are we with the use of N-acetylcysteine as a preventive and adjuvant treatment for COVID-19? Eur. Rev. Med. Pharmacol. Sci. 2022; 26 (2): 715–721. DOI: 10.26355/eurrev_202201_27898.
35. Gamarra-Morales Y., Herrera-Quintana L., Molina-López J. et al. Response to intravenous N-acetylcysteine supplementation in critically Ill patients with COVID-19. Nutrients. 2023; 15 (9): 2235. DOI: 10.3390/nu15092235.
36. Micheletto C., Izquierdo J.L., Avdeev S.N. et al. N-acetylcysteine as a therapeutic approach to post-COVID-19 pulmonary fibrosis adjunctive treatment. Eur. Rev. Med. Pharmacol. Sci. 2022; 26 (13): 4872–4880. DOI: 10.26355/eurrev_202207_29212.
37. Blasi F., Page C., Rossolini G.M. et al. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respir. Med. 2016; 117: 190–197. DOI: 10.1016/j.rmed.2016.06.015.
38. Lebeaux D., Ghigo J.M., Beloin C. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol. Mol. Biol. Rev. 2014; 78 (3): 510–543. DOI: 10.1128/MMBR.00013-14.
39. Aiyer A., Visser S.K., Bye P. et al. Effect of N-acetylcysteine in combination with antibiotics on the biofilms of three cystic fibrosis pathogens of emerging importance. Antibiotics (Basel). 2021; 10 (10): 1176. DOI: 10.3390/antibiotics10101176.
Review
For citations:
Antonov V.N., Ignatova G.L., Belsner M.S. The potential use of N-acetylcysteine in respiratory conditions. PULMONOLOGIYA. 2024;34(1):105-113. (In Russ.) https://doi.org/10.18093/0869-0189-2024-34-1-105-113
Views:
748
Email this article 